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A C-terminal cysteine residue 
is required for peptide-based 
inhibition of the NGF/trkA 
interaction at nM concentrations: 
implications for peptide-based 
analgesics
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Inhibition of the NGF/trkA interaction presents an interesting alternative to the use of non-steroidal 
anti-inflammatories and/or opioids for the control of inflammatory, chronic and neuropathic pain. 
Most prominent of the current approaches to this therapy is the antibody Tanezumab, which is a 
late-stage development humanized monoclonal antibody that targets NGF. We sought to determine 
whether peptides might similarly inhibit the NGF/trkA interaction and so serve as future therapeutic 
leads. Starting from two peptides that inhibit the NGF/TrkA interaction, we sought to eliminate a 
cysteine residue close to the C-terminal of both sequences, by an approach of mutagenic analysis 
and saturation mutagenesis of mutable residues. elimination of cysteine from a therapeutic lead is 
desirable to circumvent manufacturing difficulties resulting from oxidation. Our analyses determined 
that the cysteine residue is not required for NGF binding, but is essential for inhibition of the NGF/TrkA 
interaction at pharmacologically relevant peptide concentrations. We conclude that a cysteine residue 
is required within potential peptide-based therapeutic leads and hypothesise that these peptides likely 
act as dimers, mirroring the dimeric structure of the TrkA receptor.
Nerve growth factor (NGF) was first described over 65 years ago by Levi-Montalcini & Hamburger1 and is the 
founding member of the neurotrophin family, which play a critical role in controlling the development and sur-
vival of neuronal populations in the central and peripheral nervous system2,3. Neurotrophins act upon two classes 
of receptors; the high affinity tropomyosin receptor kinases (Trk) receptors, and the low affinity p75 neurotrophic 
receptor (p75NTR)4.
NGF is of interest to the clinical community owing to its involvement in the perception of pain. When NGF 
binds TrkA on nociceptive neurons, it activates phospholipase C, which results in sensitisation of TRPV1, a 
non-selective ligand-gated channel that generates the action potential resulting in pain signal transmission5,6. 
NGF also increases TRPV1 expression and its trafficking to the plasma membrane6,7.
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Since increased levels of NGF have been implicated in a number of pain states, including inflammatory 
and neuropathic pain8, neurogenic overactive bladder and interstitial cystitis9,10, prostatitis11, asthma12 and 
cancer-induced bone pain13, interest has focussed on creating novel analgesics by inhibiting the NGF/TrkA inter-
action. Accordingly, an anti-TrkA monoclonal antibody was shown to inhibit the perception of pain in both 
inflammatory and neuropathic pain models14. However to date, the most common NGF/TrkA intervention strat-
egies have involved sequestering NGF with monoclonal antibodies15. Such administration has shown good anal-
gesic effect in a number of animal models for human disease, such as fracture pain16, cancer pain17, pancreatic 
pain18 and arthritic joint pain19. Of the various anti-NGF antibodies in clinical trials, Tanezumab has probably 
been the most successful. It is a humanized IgG2 monoclonal antibody that binds with high affinity and speci-
ficity to NGF20. Although there have been side effect profile concerns, prompting a hold on all clinical trials of 
anti-NGF antibodies in 2010, Tanezumab was granted fast track status by the FDA in June 2017 and positive 
results from Phase 3 clinical trials have been announced recently21. A recent study has provided preliminary 
evidence that efficacy and safety of Tanezumab is similar whether delivered intravenously or subcutaneously22.
As described above, NGF binds both to TrkA (part of the Trk family of receptor tyrosine kinases) and to 
p75NTR. The Trk family share sequence homology and their extracellular regions comprise a cysteine rich 
domain (domain 1), three leucine rich repeats (domain 2), another cysteine rich cluster (domain 3) and two 
immunoglobulin (Ig)-like domains (domains 4 and 5)23. These extracellular domains are linked to an intracellular 
kinase domain via a single transmembrane helix. A sequence homology of >75% is observed for the intracellular 
kinase domain24 whilst the extracellular domains show a lesser sequence conservation of 50–55%25. NGF binds 
to domain 5 of TrkA both via a ‘specificity patch’ and a ‘conserved patch’26. Unsurprisingly, the ‘specificity patch’ 
of NGF has low sequence homology with other neurotrophins, whereas the ‘conserved patch’ contains residues 
conserved with other neurotrophins. Interestingly, neither of these patches are involved in p75NTR binding, 
which occurs via the L1, L3 and L4 loops of NGF26, again interacting with two distinct patches in the p75NTR 
receptor27–30.
Whilst the Trk receptors bind specific neurotrophins, p75NTR, a transmembrane glycoprotein, binds all 
members of the neurotrophin family31. The cytoplasmic domain of p75NTR contains a ‘death domain’, consisting 
of six α helices, that shares sequence homology to those found in other apoptosis inducing factors. Its extracel-
lular domain contains four cysteine rich domains consistent with the tumour necrosis factor receptor family32. 
The cell mediated effect of NGF-p75NTR binding is dependent on the presence or absence of TrkA. If TrkA is 
absent, NGF-p75NTR binding will lead to apoptosis33 whereas NGF- p75NTR binding in the presence of TrkA 
will increase the binding affinity of NGF to TrkA which in turn promotes survival34.
Development of novel anti-NGF peptides or peptide mimetics to inhibit the NGF/TrkA interaction, as an 
alternative to antibody therapy, would be potentially more cost-effective and/or a shorter acting addition to the 
existing arsenal of pain-modulating therapies. Indeed, the concept of developing peptide-based analgesia relating 
to the NGF-TrkA pathway is not new. Peptide-based inhibitors of the NGF-TrkA interaction were first described 
in 1995, comprising a series of short synthetic peptides cyclised via oxidation of terminal cysteine residues35. 
Later, linear cell-penetrating peptides, synthesised as HIV Tat fusions, were shown to inhibit NGF-stimulated 
TrkA phosphorylation and to suppress NGF-induced TRPV1 expression in PC12 cells36. Subsequently one of 
those peptide fusions, named IPTRK3, was shown to supress inflammatory pain in rats after local injection37 and 
cancer-induced pain in mice following intraperitoneal injection38. Peptidomimetic antagonists of TrkA have also 
been developed that prevent NGF/TrkA signalling39,40. However, recent reviews of pain therapy involving the 
NGF-TrkA pathway still focus predominantly on antibody-based (or small molecule) intervention, rather than 
peptidic alternatives41,42. Accordingly, we have produced and screened semi-saturated peptide libraries based on 
two proprietary anti-NGF peptides, that unlike the early cyclic peptides of Saragovi and co-workers35, have only 
a single cysteine residue close to their C-termini. Herein we describe the analysis of those proprietary peptides 
and our investigations into the possibility of mitigating the requirement for the C-terminal cysteine residues 
within their sequences altogether. We conclude that in common with both NGF and TrkA, cysteine residues 
play an essential role within anti-NGF peptides and as such are critical for effective inhibition of the NGF/TrkA 
interaction.
Results
Preliminary analyses of novel, proprietary, anti-NGF peptides. Initial studies within Isogenica Ltd 
had identified two synthetic 26-mer peptides, A2 and D9, that bind nerve growth factor (NGF) and inhibit bind-
ing to its receptor, TrkA. Both peptides were predicted to possess partial weakly-helical structure (Supplementary 
Information, Fig. 1a). Synthetic alanine scans were performed on each peptide and the resulting substituted 
peptides examined in a competitive ELISA. These analyses suggested that Ala substitution of residues 7, 9, 12, 13, 
16–18 and 20 of peptide A2 and residues 9, 10, 13–19 and 23 of peptide D9 diminished the inhibitory activity of 
each peptide with the effect being most pronounced at positions 9, 17, 18 & 20 and 10, 14, 17 & 23 within peptides 
A2 and D9 respectively. Meanwhile, substitution of Met1 with Ala in peptide A2 and Val8 with Ala in peptide D9 
each led to a modest increase in inhibition at 20 nM peptide concentrations, whilst Ala substitution at other posi-
tions had little or no effect (Supplementary Information, Fig. 1b). Variants of peptides A2 and D9 with truncated 
terminals were also examined for their ability to inhibit the NGF/TrkA interaction in the competitive ELISA. 
Removal of up to the first eight or up to the last six residues of peptide A2 had little/no effect on inhibition, whilst 
deletion of the final four residues 23–26 (in the presence of the residues 1–8) led to a modest increase in inhibi-
tion of the NGF/TrkA interaction by peptide A2 at 20 nM concentration. Similarly up to the first six or the last five 
residues of peptide D9 could be removed without detriment to inhibitory activity, although further deletions at 
the amino terminal of either peptide led to a reduction in inhibition (Supplementary Information, Fig. 1c). The 
sequence of peptides A2 and D9 and the results of these preliminary analyses are summarised in Fig. 1a.
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To determine residues required for NGF binding within the core of peptides A2 and D9, arrays were synthe-
sised in which each residue within an 18 aa core (Fig. 1a, dotted arrows) was individually substituted with each 
of the 20 naturally-occurring amino acids. The peptides were then examined by spot blot analysis for their ability 
to bind NGF. Examination of Fig. 1b largely confirms the findings of the preliminary alanine scan and dele-
tion analyses. For example, Tyr9 of peptide A2 and Pro10 of peptide D9 are both highly sensitive to substitution. 
However, a few discrepancies exist between the results of the two assays, most notable of which are the substitu-
tions of Cys20 and Cys23 (peptides A2 and D9 respectively). Whilst Ala substitution of these residues completely 
eliminates inhibitory activity (Fig. 1a), in each case the single cysteine residue can be substituted with any of the 
other 19 amino acids with no apparent effect on NGF binding (Fig. 1b). This difference results from the differing 
information provided by the two assays. Whilst the preliminary assays examined the peptides’ abilities to inhibit 
NGF/TrkA interaction, the spot blot simply examines the peptides’ abilities to bind NGF. Taken together, the 
analyses of parental peptide sequences suggest that the single cysteine residue near to the C terminal of each 
peptide is required for inhibition of the NGF/TrkA interaction, but is not necessary for NGF binding itself. To 
examine the role of these cysteine residues, inhibitory activity of DMSO-oxidised samples of the two 18-mer core 
sequences were compared with unoxidized samples of both the original A2 and D9 26-peptides and their 18-mer 
cores. All peptides inhibited the NGF-TrkA interaction, but inhibition was enhanced following peptide oxidation 
(Supplementary Information, Fig. 2), suggesting that the peptides function best as a dimers, presumably mediated 
via a disulfide bond between cysteine residues close to the C-terminus of each peptide.
Design and synthesis of an anti-NGF peptide library. The presence of cysteine is undesirable 
in terms of biological manufacturing and product stability, chiefly owing to its potential for oxidation and 
poorly-controlled multimerization. The preliminary alanine scanning and dot blot analyses (Fig. 1) had exam-
ined the effects of single substitutions on peptide activity. We therefore sought to determine whether an optimal 
Figure 1. Preliminary analyses of anti-NGF peptides A2 and D9. (a) Summary of findings from alanine 
scanning and deletion analyses. Key - Ala substitution: Back shading indicates the effect of alanine substitution 
on inhibition with darker shading indicating greater loss of inhibition; italics (peptide A2: positions P10 and 
V14) indicates residues not examined by alanine scanning owing to preliminary peptide synthesis failure; boxes 
indicate single residues in which substitution with alanine leads to a minor increase in inhibition at 20 nM 
peptide concentration. Source data is illustrated in the Supplementary Fig. 1. Key - deletion analyses: bold 
underlining indicates residues that may be deleted without loss of inhibition; boxing (peptide A2, COOH 
terminal) indicates the residues that when collectively deleted, lead to a minor increase in inhibition at 20 nM 
peptide concentration. Source data is illustrated in the Supplementary Fig. 1. Dotted arrows indicate the 18-mer 
peptides examined by spot blot analysis (Fig. 1b). All peptides were synthesised in house, by Isogenica Ltd. (b) 
Spot blot analysis. Peptides were spotted onto PVDF membrane and blotted with NGF and anti-NGF antibody. 
Original peptide sequences are listed across the horizontal axes and substitutions are listed by chemical 
similarity on the vertical axes. Note that each individual spot represents a single amino acid substitution 
(identified by reference to the horizontal and vertical axes). Consequently, the parental peptide sequence occurs 
once in each column and row as repeat internal controls. All peptides were synthesised at Isogenica Ltd. using 
standard Fmoc chemistry.
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combination of multiply-substituted residues in an anti-NGF peptide could mitigate the requirement for cysteine. 
If so, a synthetically-optimal anti-NGF peptide could be created.
In designing a peptide library, all three preliminary analyses (alanine scanning, deletion analysis and the sub-
stitution array) were taken into account. Both the alanine scan (Supplementary Information, Fig. 1b,c) and the 
substitution array (Fig. 1b) confirm that individual substitution of residues 1–6 or 19–22 with alanine in either 
peptide can be achieved without detriment to NGF binding (albeit that substitution of the cysteine residues elim-
inates inhibitory activity), whilst deletion of residues 23–26 of peptide A2 is mildly advantageous, as described 
above. Meanwhile, examination of Fig. 1a shows that both peptides A2 and D9 contain a central motif (residues 
7–18) in which ten of the twelve amino acids are identical and the substitution array indicates the degree of indi-
vidual substitutions that can be tolerated at each of these positions.
A 22-mer anti-NGF peptide library with conserved residues in positions 1–7, 10 and 19–22 was therefore 
designed to combine the results of all three analyses. The library was synthesised using ProxiMAX randomisa-
tion, in two sections (Fig. 2a) which were subsequently joined by blunt-end ligation. ProxiMAX randomisation 
Figure 2. Anti-NGF peptide library design and synthesis. (a) Design of anti-NGF peptide library. (b) Expected 
(Exp) versus observed (Obs) amino acid frequencies encoded within the anti-NGF gene library. The library 
was synthesised in two sections (left and right hand sides) with five and six cycles of addition respectively, as 
described in Materials and Methods, using manual, equimolar additions of MAX hairpin oligonucleotides, 
followed by blunt-end ligation of the two library fragments. Codon frequencies were determined by Illumina 
Miseq analysis of full length amplicons (n = 326047 sequences). (c) Additional library statistics. (i) Lengths of 
the most common library products. (ii) Frequencies of repeated sequences within the 326047 full-length library 
products.
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is advantageous since, in contrast to conventional saturation mutagenesis, it is a non-degenerate process that 
allows the user to encode only selected amino acids at each saturated position, thereby creating the smallest 
possible library while covering all desired mutations. We have previously described ProxiMAX technology and 
its application via both manual and automated single (trimer) additions and automated double-codon (hexamer) 
additions43,44. Herein, we employed manual, equimolar trimer additions as described in Materials and Methods. 
The quality of the finished library was assessed by next generation sequencing (Fig. 2b). As previously anticipated, 
ProxiMAX randomisation via manual, equimolar addition of trimers is not so precise as the automated variant or 
indeed the manual or automated addition of hexamers. Nonetheless, the resulting library showed acceptable cor-
relation between the expected and observed codon frequencies. The library had a calculated diversity of 68.7%45. 
Further library statistics are illustrated in Fig. 2c.
Library selection and screening strategy. The major bottleneck in traditional directed evolution is the 
ability to screen the gene libraries efficiently. In order to screen a large mixture of putative inhibitors such as is 
created by saturation mutagenesis, a high-throughput assay format is essential. In vitro, cell-free selection meth-
ods offer greater ability to probe sequence space and when combined with high-quality libraries, maximise the 
probability of finding optimised mutants. Conversely, the competitive ELISA assay that was used to screen the 
original alanine-substituted peptides for inhibition of the NGF/TrkA interaction is strictly a low throughput assay 
that can provide useful data only when used to analyse individual inhibitors. Accordingly, the anti-NGF library 
was expressed and screened in a three-stage process. The initial screen, using CIS-display46 served to enrich a 
maximal size, oversampled library for mutants retaining NGF binding. In the second-stage, phage display/ELISA 
were used to eliminate weak and/or non-specific binders. Finally, individual peptides identified from the first two 
stages were chemically synthesised without C-terminal extensions (RepA or gene III in CIS and phage display 
formats, respectively) and examined via competitive ELISA for their ability to inhibit the NGF/TrkA interaction. 
Each of these stages are addressed below.
Library enrichment through CIS Display. CIS display expresses library genes as fusions to the bacterial 
replication initiator protein, RepA in an in vitro translation and transcription (ITT) system that also includes the 
DNA elements RepA binds to in CIS. This creates a phenotype/genotype link by exploiting RepA’s ability to bind 
to its encoding DNA in cis46. The anti-NGF library (Fig. 2), encoding a theoretical total of 13.5 million variant 
peptides, was subjected to four rounds of CIS display against an immobilised recombinant human NGF (rhNGF) 
target, with the stringency of selection conditions progressively increasing through each round, as described in 
Materials and Methods. The output of the CIS display selections were then inserted into phagemids, yielding 
approximately 2500 clones.
Assessment of peptide specificity for NGF via phage display/ELISA. Although increasing in strin-
gency through each round, and despite blocking the microtitre wells, like any panning procedure, the CIS-display 
protocol has the potential to carry expressed peptides with weak or even non-specific interactions through to the 
next round of screening. Accordingly, phage display/ELISA was next employed to select specific binders from the 
enriched library. Approximately 250 clones were chosen and screened via phage display/ELISA for the ability to 
bind specifically to immobilised rhNGF. Subsequent DNA sequencing of the 32 resulting positive clones revealed 
12 twelve independent sequences that were compliant with the library design and exhibited specific NGF binding 
(Fig. 3). Interestingly, a few frameshifted mutants that contained one or more cysteine residues were also identi-
fied amongst the specific peptides. However, since we aimed to eliminate cysteine from the peptide design, only 
representatives of the twelve compliant sequences were taken forward to the final stage of screening.
Assessment of peptide-based inhibition of the NGF/TrkA interaction via competitive ELISA. 
The ability to bind NGF specifically is a preliminary assay in the current context, since NGF binding activity does 
not necessarily translate into the ability to inhibit the NGF/TrkA interaction. Therefore, each unique peptide 
sequence was chemically synthesised and assessed for its inhibitory activity via competitive ELISA. Interestingly, 
whereas the inhibitory concentration of the original, cysteine-containing peptides was in the nanomolar range, 
with full inhibition of the NGF/TrkA interaction being achieved at 100 nM concentrations (Supplementary 
Figure 3. Assessment of peptide specificity for NGF via phage display/ELISA. Two hundred and fifty phage 
clones were analysed by ELISA for their ability to bind to a microtitre well in the presence (black bars) 
or absence (grey bars) of immobilised NGF as described in Materials and Methods. Results from the 12 
independent, library-compliant, positive clones that showed specific NGF binding are illustrated. Negative 
controls: −ve 1, non-recombinant phage; −ve 2, PBS buffer control (no phage).
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Information, Fig. 1), none of the selected, cysteine-free peptides showed any inhibition at these concentrations 
(data not shown). Wider-ranging dose curves from μM to mM concentrations were therefore prepared for each 
of these peptides. As shown in Fig. 4, four peptides inhibited the NGF/TrkA interaction partially, albeit at these 
higher concentrations. A comparison between the sequences of the 12 NGF-binding peptides and the subset of 
four peptides that both bind NGF and inhibit the NGF/TrkA interaction (albeit at elevated concentrations) is 
illustrated in Fig. 5.
The far higher effective concentration required for inhibition by the selected peptides, coupled with the 
re-emergence of cysteine-containing peptides from the second stage screen, suggests that even multiple muta-
tions cannot substitute for a C-terminal cysteine residue and that the latter is indeed required within a peptide 
in order to inhibit the interaction between NGF and TrkA at reasonable peptide concentrations. To confirm this 
hypothesis, deletion studies of the core 18-mer of peptide A2 (Fig. 1b) were performed. The cysteine residue 
Figure 4. Inhibition of the NGF/TrkA interaction by peptides AP3, AP6, AP7 and AP9. (a) Competitive 
ELISAs. Each of the twelve chemically-synthesised peptides was incubated with NGF and the mixture added 
to a plate containing immobilised TrkA. After washing, NGF binding to TrkA was detected via a biotinylated, 
anti-NGF antibody, streptavidin/HRP conjugate and TMP chromogenic reagent, as described in Materials and 
Methods. Dose response curves are shown for the four peptides, AP3, AP6, AP7 and AP9 that inhibited the 
NGF-TrkA interaction successfully. All reactions were performed in triplicate. Error bars represent standard 
deviations. (b) Sequences of the inhibitory peptides.
Figure 5. Comparison of non-cysteine-containing peptide sequences selected from anti-NGF library screening 
that bind NGF, ±inhibition of the NGF/TrkA interaction. Frequency plots illustrate consensus sequences of 
the saturated region of the twelve NGF-binding peptides assessed in Fig. 3 and the subset of four anti-NGF 
inhibitory peptides assessed in Fig. 4. Plots were created using the UC Berkeley Weblogo tool (http://weblogo.
berkeley.edu/logo.cgi).
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is three amino acids away from the C-terminal of this peptide. Therefore the core A2 18-mer and consecutive 
single amino acid C-terminal deletions were synthesised to encompass the cysteine residue. Dose curves were 
then constructed using the NGF-TrkA inhibition ELISA described previously. The effect of the cysteine residue is 
dramatic. In fact, truncation of this peptide has little/no effect on inhibition until the cysteine is removed (Fig. 6). 
Moreover, lack of inhibition is not merely an effect of truncation: peptide A2-18-2 (Fig. 6, green) which has a 
cysteine residue at the extreme C-terminus is almost as effective in inhibiting the NGF/TrkA interaction as the 
core A2 18-mer itself (Fig. 6, red). Conversely, replacement of that cysteine with alanine, even though the peptide 
is of the same length, or truncation of the terminal cysteine residue, each reduce inhibition of the NGF/TrkA 
interaction by three orders of magnitude (Fig. 6, magenta and yellow respectively).
Discussion
Like most other members of neurotrophin family, including brain-derived neurotrophic factor (BDNF)26,47, 
neurotrophin-3 (NT-3)26,48, neurotrophin-4/5 (NT-4/5)26,49 and neurotrophin-6 (NT-6)26,50, biologically active 
(beta) NGF exists as a parallel homo-dimer of two NGF monomers26. The NGF dimer binds two molecules of 
TrkA by making multiple contacts with the extracellular, Ig-like domain 5 of TrkA (TrkA d5) via two specific 
areas. Residues 2–13 at the N-terminal of NGF bind to the ‘specificity patch’ of TrkA, which comprises the face 
of the ABED β-sheet of TrkA d526. Interestingly, in the unbound state, these N-terminal residues of NGF are 
disordered, but form a short segment of α-helix when bound to the specificity patch of TrkA. The importance of 
this interaction for the activity of NGF is demonstrated by deletion of the first ten N-terminal residues of NGF, 
which causes a 300-fold drop in affinity for TrkA47–51, whilst a 9-fold decrease in affinity is caused by deletion 
of the first five residues48–52. Thus it is tempting to speculate that anti-NGF peptides might interact with these 
N-terminal residues of NGF and in so doing, prevent their interaction with TrkA d5. Meanwhile, residues in the 
central β sheet region or ‘waist’ of NGF bind to the ‘conserved patch’ of TrkA d5, which comprises the AB, C’D 
loops and particularly the EF loop of TrkA d5 which are all found at one end of TrkA d5 domain49–53. It is in this 
EF loop in which the highest degree of conservation between the Trk receptors is found, with 9 of 11 residues 
conserved across all three receptors TrkA, TrkB and TrkC50–54. As such, inhibition of that interaction will likely 
be undesirable.
Clearly, in the absence of structural data, the mechanism by which parental peptides A2 and D9 inhibit the 
NGF/TrkA interaction cannot be elucidated fully. Either peptide might prevent binding between the N-terminal 
of NGF with the specificity patch of TrkA, or the ‘waist’ of NGF with the conserved patch of TrkA (or even, 
potentially, both interactions). However, the decreased ability by the non-cysteine-containing peptides isolated 
in this study to inhibit the NGF/TrkA interaction, compared to the cysteine-containing parental peptides, argue 
strongly in support of the original hypothesis, namely that the inhibitory peptide itself ideally acts as a dimer. This 
hypothesis is further supported by the enrichment of cysteine-containing frameshift mutants in the display assays 
and is logical in terms of the homo-dimeric structure of NGF itself.
However, our results have also demonstrated clearly that the C-terminal cysteine is not required for NGF 
binding per se. Thus an alternative explanation for inhibition also exists with respect to NGF structure. Each NGF 
monomer (118 amino acids) contains two pairs of twisted, anti-parallel β- strands. Two such monomers form a 
dumbbell-shaped homodimer. At the bottom, membrane-facing end of the dumbbell, there are three β-hairpin 
loop structures (L1, L2 and L4), whilst the ‘waist’ is formed by the central β-sheets of the NGF homo-dimer26. 
Figure 6. The effect of C-terminal truncation of peptide A2 on the inhibition of the NGF/TrkA interaction. 
Competitive ELISAs. Each peptide was incubated with NGF and the mixture added to a plate containing 
immobilised TrkA. After washing, NGF binding to TrkA was detected via a biotinylated, anti-NGF antibody, 
streptavidin/HRP conjugate and TMP chromogenic reagent, as described in Methods. The sequences of 
each truncated peptide are shown. All reactions were performed in triplicate. Error bars represent standard 
deviations.
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Meanwhile, at the top of the dumbbell are both the N- and C- terminals, a β-hairpin loop structure (L3) and a 
cysteine knot. The latter comprises three disulfide bonds, two of which form a closed ring with the third pene-
trating the ring. These confer stability to the molecule and interestingly have been found in other dimeric growth 
factors, such as platelet-derived growth factor and transforming growth factor-β, which do not share any other 
significant sequence homology with the neurotrophin family26. Once the inhibitory peptide has bound NGF via 
the majority of its residues, might the single cysteine at the C-terminus of the peptide interfere with the cysteine 
knot, either via labile redox chemistry, metal chelation effects or even a formal disulfide exchange reaction? Any 
such modification would be reversible but would likely effect both the structure and stability of NGF. The data, 
namely that peptides lacking a C-terminal cysteine can nevertheless inhibit the NGF/TrkA interaction (albeit at 
elevated concentrations), argue against such a model, but clearly, future structural data will be required to resolve 
this question unequivocally.
Conclusions
Our data confirm that several related peptide sequences can bind to NGF and that NGF-binding does not neces-
sarily equate to inhibition of the NGF/TrkA interaction. Conversely, we conclude that a cysteine residue located 
close to the C-terminal of a binding peptide is critical for effective inhibition of the NGF/TrkA interaction, but is 
not itself required for NGF binding. Further, we demonstrate that both cysteine-containing peptide monomers 
and dimers inhibit the NGF/TrkA interaction, but that inhibition is enhanced in the presence of the dimeric 
forms of the peptides, relative to the monomeric forms.
Future structural studies will be required to confirm the mode of action of the peptides described herein and 
indeed any other peptide-based leads. Clearly, an effective peptide-based inhibitor would be required to inhibit 
the interaction between the N-terminal of NGF and the specificity patch of TrkA, rather than that between the 
waist of NGF and the conserved patch of TrkA, since the latter shares a high degree of homology with other Trk 
receptors.
In the meantime, those seeking to develop non-antibody, lead compounds for pain relief via the NGF/
TrkA pathway may need to compromise manufacturing ideals and include a C-terminal cysteine residue into 
peptide-based inhibitors.
Methods
ProxiMAX Randomised Anti-NGF Peptide Library Construction. Appropriate self-hybridised MAX 
hairpin stocks43 (2.4 µM) were ligated individually to 0.4 µM base sequence, in a 20 µl reaction containing 1 
Thermo Scientific ligase buffer, 5% w/v PEG (Thermo Scientific) and 5 µl T4 DNA ligase (Thermo Scientific) and 
incubated at 22 °C for 15 min followed by 65 °C for 10 minutes.
Quadruple 100 µl amplifications were set up containing 50 pmol primers (the appropriate cycle primer and a 
universal primer for the base sequence), 20 µM dNTPs, 2 units Phusion Hot Start II high-fidelity DNA polymer-
ase (Thermo Scientific), 1 × Phusion HF buffer and 8 µl of the single hairpin ligation. These underwent initial 
denaturation at 98 °C for 45 secs followed by 3 cycles of (98 °C, 10 s; 52 °C, 30 s; 72 °C, 20 s), 13 cycles of (98 °C, 
10 s; 55 °C, 30 s; 72 °C, 20 s) and a final extension of 72 °C for 8 min. The four PCR reactions were combined and 
purified using a QIAquick PCR Purification Kit (Qiagen) according to manufacturer’s instructions. DNA con-
centration was quantified by UV using a nanodrop 2000c (Thermo Scientific), PCR products were then mixed to 
give an equimolar mix of MAX hairpins.
The equimolar mix was digested in a 50 µl reaction containing 1x fast digest buffer and 10 units MlyI (Thermo 
Scientific). The reaction was incubated at 37 °C for 1 hr and then 65 °C for 20 min, and the resulting product was 
electrophoresed of a 3% agarose/TAE gel to check the digestion was successful and purified by agarose gel extrac-
tion. The concentration of the digested product was quantified by UV. This process was then reiterated using the 
digested material as the template sequence for the following cycle of additions.
CIs display selections. The ProxiMAX generated peptide library was then extended on 5′ and 3′ ends 
with promotor and RepA/CIS/ori regions encoding DNA, respectively46. Next, an in vitro transcription/transla-
tion reaction (ITT) was set up containing 2 μg library template DNA along with in Isogenica proprietary buffer, 
amino acid mix and cell lysate to a total volume of 50 μl, and incubated for 1 hour at 37 °C and on ice for 5 min-
utes. Dynabeads® M-280 Streptavidin (Life technologies) were prewashed 3x with PBS and resuspended in the 
original volume of 2% BSA/PBS/0.1%Tween (PBST). Non-specific binders were deselected by mixing the ITT for 
30 minutes with 2% BSA/PBS (+/−1 mg/ml heparin depending on stringency) and uncoated magnetic beads. 
These magnetic beads were then removed using a magnet, yielding deselected ITT supernatant. In parallel, bioti-
nylated rhβ-NGF (10 μg) was bound to 50 μl prewashed beads for 1 hour in PBS followed by 2x PBS washes and 
blocked with 2% BSA/PBS. Deselected ITT supernatant was mixed with rhβ-NGF precoated beads and washed 
on a KingFisher™ Flex Magnetic Particle Processor (Thermo Scientific). Bead-bound DNA was heat eluted at 
75 °C in 1x ThermoPol buffer for 10 minutes, the beads were captured and the supernatant transferred to a fresh 
Eppendorf tube.
Eluted DNA was PCR amplified using reactions containing 10 μM recovery primer, 2 µM dNTPs, 1 x KOD 
buffer, 25 mM MgSO4, 0.5 units KOD Hot Start DNA polymerase (Merck Millipore Millipore) and 10 µl of the 
eluted DNA. These underwent initial denaturation at 95 °C for 2 min followed by 35 cycles of (95 °C, 30 s; 52 °C, 
20 s; 72 °C, 1 min), and a final extension of 72 °C for 7 min. The resulting product was purified using Promega 
WizardTM columns according to the manufacturer’s protocol and the purified DNA was used for another round 
of selections.
peptide dot blot analysis. Peptides were synthesised in house at Isogenica and spotted on a PVDF mem-
brane, which was air-dried and then blocked by incubation in 0.1% casein, 4% sucrose, 0.1% Tween at 4 °C, 
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overnight. The membrane was washed with TBS/tween (3 × 5 min) and TBS (2 × 5 min) and incubated with NGF 
(3 ng/µl in 0.1% casein/TBS/Tween) at room temperature for 1 hr. The washing steps were repeated and the mem-
brane incubated with 0.025 ng/µL of biotinylated anti-human b-NGF antibody in 0.1% casein/TBS/Tween at 
room temperature for 1 hr. The washing steps were again repeated and immobilised antibody was then detected 
using a Strep-Tactin AP detection kit (IBA Lifesciences, cat# 2-1503-000) according to manufacturer’s instruc-
tions. All incubations were performed on a rocking platform.
phage screening of CIs Display selection output. Final selection round output DNA was then ligated 
into a standard phagemid vector and transfected into E. coli. Transfected E. coli were plated in selective medium. 
Individual colonies were then picked into 120 μl 2TY with 100 μg/ml ampicillin and 2% glucose. This was incu-
bated at 37 °C, 225 rpm until cloudy. Glycerol was then added to 25% (v/v) and these precultures were stored at 
−80 °C.
Preculture (30 μl) was transferred to 300 μl 2TY-Amp-Glu and incubated at 37 °C until the OD600nm was 0.3. 
Approximately 108 pfu (plaque forming units) of M13K07 helper phage (NEB) was added and incubated at 37 °C 
with shaking at 225 rpm. The cultures were pelleted by centrifugation at 3000 × g for 10 mins, the supernatant 
discarded and pellets resuspended in 600 μl 2TY-Amp. This was subsequently incubated at 37 °C, with shaking 
at 225 rpm overnight and the following day the cultures were pelleted by centrifugation at 3000 × g for 10 mins. 
Phage-containing supernatant was analysed by ELISA.
A NUNC F96 Maxisorp plate (Sigma-Aldrich) was coated with 50 ng/well recombinant human β-NGF (R&D 
Systems) and incubated overnight at 4 °C. The plate was washed 4x PBST and 2x PBS and blocked for 1 hr at room 
temperature with BlockerTM 1% casein in PBS (Thermo Scientific #37528) followed by 4x washes with PBST and 
2x PBS. Supernatant produced from phage expression was diluted 1/2 in 0.1% casein in PBS/0.1% Tween, 100 μl/
well was added to the Maxisorp plate and incubated at room temperature for 1 hour. The plate was washed with 
4x PBST and 2x PBS. Mouse anti-M13 HRP conjugated antibody (Sigma-Aldrich; 1:5000 dilution, 50 µl/well) in 
0.1% casein/PBST was incubated on the plate for 30 minutes at room temperature followed by 4x washes with 
PBST and 2x PBS. TMB reagent (Thermo Scientific #34028; 50 µl/well) was incubated on the plate for 5–20 min-
utes, the reaction was quenched with 50 µl/well 0.5 M H2SO4 and the absorbance read at 450 nm.
Competitive ELISA analysis of synthetic peptides. Recombinant human TrkA-Fc chimera 
(125 ng/50 μl; R&D Systems, 175-TK) was coated onto NUNC F96 Maxisorp ELISA plates (Sigma-Aldrich) at 
4 °C overnight. The plate was washed 3x in PBST and 2x PBS and then blocked for 1 hr at room temperature 
with BlockerTM 1% casein in PBS (Thermo Scientific #37528), followed by 4x washes with PBST and 2x PBS. 
Thirty ng recombinant human β-NGF (R&D Systems, 256-GF/CF) was mixed with 50 µl peptide (Isogenica or 
Alta Biosciences, UK) at appropriate concentration in 0.1% casein in PBS/0.1% Tween. NGF/peptide solutions 
(55 µl/well) were transferred into the NUNC Maxisorp plate and incubated for 40 minutes at room tempera-
ture with 50 µl/well 1:200 diluted biotinylated anti-human β-NGF antibody (R&D Systems, 256-GF/CF) in 0.1% 
casein in PBS/0.1% Tween. The plate was washed 4x in PBST and 2x PBS. Streptavidin-HRP (Sigma-Aldrich; 
Streptavidin-Peroxidase Polymer, Ultrasensitive, #2438; 1:1000 dilution, 50 µl/well) in 0.1% casein/PBST was 
incubated on the plate for 30 minutes at room temperature followed by 4x washes with PBST and 2x PBS. TMB 
reagent (Thermo Scientific #34028; 50 µl/well) was incubated on the plate for 5–20 minutes, quenched with 50 µl/
well 0.5 M H2SO4 and the absorbance read at 450 nm.
Data Availability
Source data for Fig. 1 is presented in Supplementary Fig. 1. Source data for Supplementary Figs 1 and 2 and 
Figs 2–4 and 6 are available in the Aston Data Explorer and may be accessed via the following link https://doi.
org/10.17036/researchdata.aston.ac.uk.00000375. Source data for Fig. 5 is contained within the manuscript. Oth-
er datasets generated and/or analysed during the current study are available in the Aston Research Explorer and 
may be accessed via the following link: http://publications.aston.ac.uk/28900/1/Poole_Andrew_J._2016.pdf.
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